PET/CT with <sup>18</sup>F-PSMA in Patients with Prostate Cancer, Review of the Initial Experience

Abstract

METHOD:We carry out an observational study where reviewed the PET/CT studies with PSMA marked with Fluor-18 ( 18 F) carried out from February 2019 to September 2020. We analyzed the average value of hepatic uptake SUV lean average (SUVlave), acquisition time, age, reason from the study, focal, multifocal and diffuse prostate uptake, analysis of the location of metastases, level of prostate specific antigen (PSA), we describe uptakes of non-prostate origin and focal uptakes in ribs without anatomical representation. RESULTS: The average hepatic SUVlave was 9.7, the acquisition times were variable (52 -183 minutes) without alterations in the white-background relationship, the most frequent indication for the study was staging, the uptake in ribs without anatomical representation were considered benign with certain characteristics, PET/CT has the ability to detect neoplastic activity with low PSA levels in lymph nodes < 5 mm and bone metastatic status. CONCLUSION: PET/CT with 18 F-PSMA has advantages over bone scan and computed tomography of the abdomen and pelvis for the staging of prostate cancer.